Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-10-2013 | Original Paper

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

Authors: Liang-Hao Guo, Panagiotis Alexopoulos, Robert Perneczky

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2013

Abstract

The main objective of the study was to validate the findings of previous cerebrospinal fluid (CSF) proteomic studies for the differentiation between Alzheimer’s disease (AD) dementia and physiological ageing. The most consistently significant proteins in the separation between AD dementia versus normal controls using CSF proteomics were identified in the literature. The classification performance of the four pre-selected proteins was explored in 92 controls, 149 patients with mild cognitive impairment (MCI), and 69 patients with AD dementia. Heart-type fatty acid binding protein (hFABP) and vascular endothelial growth factor (VEGF) CSF concentrations distinguished between healthy controls and patients with AD dementia with a sensitivity and specificity of 57 and 35 %, and 76 and 84 %, respectively. The optimal classification was achieved by a combination of the two additional CSF biomarker candidates in conjunction with the three established markers Amyloid-β (Aβ)_1–42, total-Tau (tTau), and phosphorylated-Tau (pTau)₁₈₁, which resulted in a sensitivity of 83 % and a specificity of 86 %. hFABP also predicted the progression from MCI to AD dementia. The present study provides evidence in support of hFABP and VEGF in CSF as AD biomarker candidates to be used in combination with the established markers Aβ_1–42, tTau, and pTau₁₈₁.

Available only for authorised users

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289–300

Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers dis 27:665–676PubMed

Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Dis 21:9–15CrossRef

Blennow K, Zetterberg H (2009) Cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers dis 18:413–417PubMed

Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–144PubMedCrossRef

Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T (2011) Modeling of pathological traits in Alzheimer’s disease based on systemic extracellular signalling proteome. Mol Cell Proteomics 10:M111.008862PubMedCrossRef

Burger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, Yafai Y, Schliebs R (2009) Vascular endothelial growth factor (vegf) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic tg2576 mouse brain. Int J Dev Neurosci 27:517–523PubMedCrossRef

Catelan D, Biggeri A (2010) Multiple testing in disease mapping and descriptive epidemiology. Geospat health 4:219–229PubMed

Cheon MS, Kim SH, Fountoulakis M, Lubec G (2003) Heart type fatty acid binding protein (h-fabp) is decreased in brains of patients with down syndrome and Alzheimer’s disease. J neural transm Suppl 67:225–234PubMedCrossRef

10.

Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K (2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers dis 22:1281–1288PubMed

11.

Chin AL, Negash S, Hamilton R (2011) Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord 25:187–195PubMedCrossRef

12.

Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS ONE 6:e18850PubMedCrossRef

13.

Guo LH, Alexopoulos P, Eisele T, Wagenpfeil S, Kurz A, Perneczky R (2012) The national institute on Aging–Alzheimer’s association research criteria for mild cognitive impairment due to Alzheimer’s disease: Predicting the outcome. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-012-0349-0

14.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathol 120:385–399PubMedCrossRef

15.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Novel csf biomarkers for Alzheimer’s disease and mild cognitive impairment. Acta Neuropathol 119:669–678PubMedCrossRef

16.

Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of ad patients using beta-amyloid(1–42) and tau levels in csf. Neurology 52:1555–1562PubMedCrossRef

17.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS (2011) Evidence for ordering of alzheimer disease biomarkers. Arch Neurol 68:1526–1535PubMedCrossRef

18.

Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD (1998) Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Res Mol Brain Res 62:101–105PubMedCrossRef

19.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, Dechairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ (2011) Genome-wide association study of csf biomarkers a{beta}1-42, t-tau, and p-tau181p in the adni cohort. Neurology 76:69–79PubMedCrossRef

20.

Lescuyer P, Allard L, Hochstrasser DF, Sanchez JC (2005) Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke. Mol diagn 9:1–7PubMedCrossRef

21.

Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260:561–562PubMedCrossRef

22.

Matsui Y, Satoh K, Mutsukura K, Watanabe T, Nishida N, Matsuda H, Sugino M, Shirabe S, Eguchi K, Kataoka Y (2010) Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the csf of cjd patients. Cell Mol Neurobiol 30:991–999PubMedCrossRef

23.

Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M (2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with lewy bodies. Neurodegener dis 4:366–375PubMedCrossRef

24.

Morris JC, McKeel DW Jr, Fulling K, Torack RM, Berg L (1988) Validation of clinical diagnostic criteria for Alzheimer’s disease. Ann Neurol 24:17–22PubMedCrossRef

25.

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. Dement geriatr cogn dis extra 1:31–42PubMedCrossRef

26.

Otto M, Lewczuk P, Wiltfang J (2008) Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 44:289–298PubMedCrossRef

27.

Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF (2004) Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 50:1568–1575PubMedCrossRef

28.

Provias J, Jeynes B (2011) Correlation analysis of capillary apoe, vegf and enos expression in alzheimer brains. Curr Alzheimer Res 8:197–202PubMedCrossRef

29.

Radebaugh T, Khachaturian ZS (1998) Consensus report of the working group on: “Molecular and biochemical markers of Alzheimer’s disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s association and the National Institute on Aging Working Group. Neurobiol Aging 19:109–116

30.

Roman GC (2004) Vascular dementia. Advances in nosology, diagnosis, treatment and prevention. Panminerva Med 46:207–215PubMed

31.

Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89:607–648PubMedCrossRef

32.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative Subjects. Ann Neurol 65:403–413PubMedCrossRef

33.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597–609PubMedCrossRef

34.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimers dement 7:280–292PubMedCrossRef

35.

Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370:36–39PubMedCrossRef

36.

Storch J, Thumser AE (2010) Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 285:32679–32683PubMedCrossRef

37.

Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440–9445PubMedCrossRef

38.

Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging 23:237–243PubMedCrossRef

39.

Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark med 4:65–79PubMedCrossRef

40.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM (2010) Update on the biomarker core of the Alzheimer’s disease neuroimaging initiative subjects. Alzheimers dement 6:230–238PubMedCrossRef

41.

Veerkamp JH, Zimmerman AW (2001) Fatty acid-binding proteins of nervous tissue. J mol neurosci 16:133–142 discussion 151–137PubMedCrossRef

42.

Vidoni ED, Townley RA, Honea RA, Burns JM (2011) Alzheimer disease biomarkers are associated with body mass index. Neurology 77:1913–1920PubMedCrossRef

43.

Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hull M, Frolich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schroder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78:379–386PubMedCrossRef

44.

Wunderlich MT, Hanhoff T, Goertler M, Spener F, Glatz JF, Wallesch CW, Pelsers MM (2005) Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718–724PubMedCrossRef

45.

Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer’s disease. Neurobiol Aging 25:283–290PubMedCrossRef

46.

Zanier ER, Longhi L, Fiorini M, Cracco L, Bersano A, Zoerle T, Branca V, Monaco S, Stocchetti N (2008) Increased levels of CSF heart-type fatty acid-binding protein and tau protein after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 102:339–343PubMedCrossRef

47.

Zellner M, Veitinger M, Umlauf E (2009) The role of proteomics in dementia and alzheimer’s disease. Acta Neuropathol 118:181–195PubMedCrossRef

48.

Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am j of clinical pathology 129:526–529CrossRef

49.

Zolg W (2006) The proteomic search for diagnostic biomarkers: lost in translation? Mol Cell Proteomics 5:1720–1726PubMedCrossRef

Title: Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease
Authors: Liang-Hao Guo
Panagiotis Alexopoulos
Robert Perneczky
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2013
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-013-0405-4

At a glance: The STEP trials

Springer Medicine

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases

Brain activation deficit in increased-load working memory tasks among adults with ADHD using fMRI

Brain volumes differ between diagnostic groups of violent criminal offenders

High prevalence of brain pathology in violent prisoners: a qualitative CT and MRI scan study

Systematic review of the diagnostic utility of SPECT imaging in dementia

Regional cerebral changes and functional connectivity during the observation of negative emotional stimuli in subjects with post-traumatic stress disorder